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Abstract: The diffusion of the legalization of cannabis for recreational, medicinal and nutraceutical 
uses requires the development of adequate analytical methods to assure the safety and security of 
such products. In particular, aflatoxins are considered to pose a major risk for the health of cannabis 
consumers. Among analytical methods that allows for adequate monitoring of food safety, 
immunoassays play a major role thanks to their cost-effectiveness, high-throughput capacity, 
simplicity and limited requirement for equipment and skilled operators. Therefore, a rapid and 
sensitive enzyme immunoassay has been adapted to measure the most hazardous aflatoxin B1 in 
cannabis products. The assay was acceptably accurate (recovery rate: 78–136%), reproducible (intra- 
and inter-assay means coefficients of variation 11.8% and 13.8%, respectively), and sensitive (limit 
of detection and range of quantification: 0.35 ng mL−1 and 0.4–2 ng mL−1, respectively corresponding 
to 7 ng g−1 and 8–40 ng g-1 ng g−1 in the plant) and provided results which agreed with a HPLC-
MS/MS method for the direct analysis of aflatoxin B1 in cannabis inflorescence and leaves. In 
addition, the carcinogenic aflatoxin B1 was detected in 50% of the cannabis products analyzed (14 
samples collected from small retails) at levels exceeding those admitted by the European Union in 
commodities intended for direct human consumption, thus envisaging the need for effective 
surveillance of aflatoxin contamination in legal cannabis. 
Keywords: mycotoxins; food safety; medicinal herbs; competitive immunoassay 
Key Contribution: A rapid and sensitive enzyme immunoassays has been established to measure 
aflatoxin B1 contamination in cannabis products. The hazardous aflatoxin B1 has been detected in 
50% of cannabis products analyzed by the developed method thus highlighting the need of 
surveillance. A discussion of methods to define the limit of detection and quantification range of 
competitive immunoassays is also provided. 
 
1. Introduction 
Cannabis sativa is a plant of the Cannabaceae family and is well-known for its content of 
biologically active chemical compounds, among which the major compounds are delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD). The flowering or fruiting tops of the Cannabis 
plant have been controlled under the Controlled Substances Act since 1970 under the drug class 
“Marihuana” [1]. 
Cannabis products can be used for medicinal purposes (whether the psychoactive THC or the 
non-psychoactive CBD, generally referred to as ‘medical cannabis’), in manufacturing (‘industrial 
hemp’) and for non-medical intoxication (‘recreational or psychoactive cannabis’) [2]. The number of 
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active components found in cannabis and the variety of their effects have also suggested its potential 
use as a dietary supplement and nutraceutical [3,4]. According to the World Health Organization 
(WHO), recreational cannabis is the most widely used illicit drug and the most largely cultivated and 
trafficked worldwide [5]. 
The therapeutic application of cannabis is increasing across the world [6]. A medicine based on 
cannabis extract has been approved by the European Medicines Agency [7]. THC for medical 
application can be administered as capsules, mouth spray or as flowers for making tea. The US 
Federal Drug Administration (FDA) has approved one cannabis-derived and three cannabis-related 
drug products [8]. 
The cultivation and supply of cannabis for industrial use is legal in the European Union since 
2013, provided there is a THC content not exceeding 0.2% [9]. In 2018, USA liberalized the production 
and marketing of hemp, provided that THC content is below 0.3% on a dry weight basis [1]. 
Advances in liberalization of the use of cannabis for recreational purposes and as dietary 
supplement and the increase in medical applications are expected to favor the growth of the global 
legal market of such product in the next years. However, the toxicity to humans of common cannabis 
contaminants is largely unknown. Due to the ambiguity between legal and illicit production and 
supply of cannabis products, there is significant lack in the literature regarding the prevalence of 
cannabis contaminants and of their harmfulness to humans. Contemporarily, progress in the 
diffusion of cannabis products demands further research in this area, especially because they are used 
for therapy. [10] 
Several classes of contaminants can be present in cannabis including: heavy metals, which are 
able to bio-accumulate in the cannabis plants [11]; pesticides, (which may also include illegal 
pesticides because cannabis has been considered illegal for a long time and, therefore, pesticide 
guidelines or maximal limits for pesticide residues have not been set for this substrate); 
microbiological contaminants and toxins from microbial overloads, such as ochratoxins and 
aflatoxins [12,13]. 
McKernan et al. showed that toxigenic fungi grow on cannabis (especially those producing 
aflatoxin and ochratoxin) and highlighted the need to investigate the presence of the corresponding 
mycotoxins in these kinds of sample [14]. Among mycotoxins that can affect cannabis, aflatoxins 
(AFs) are of utmost concern because of their toxicity and their widespread distribution. AFs are 
carcinogens, genotoxic and immunosuppressive agents [15]. In particular, aflatoxin B1 (AFB1) is the 
most recurrent and carcinogenic of the aflatoxins, and it is well documented to be a causative agent 
of hepatocellular carcinoma as well as growth suppression, immune system modulation, and 
malnutrition [16,17]. AFB1 is produced by fungi of the Aspergillus genus, namely Aspergillus flavus 
and Aspergillus parasiticus. 
A. flavus is ubiquitously found in soil and contaminates a wide range of the world’s crops. After 
establishing the plant as a host, the fungus produces aflatoxins, including AFB1. Fungal growth can 
occur on crops at any point in the pre- or post-harvest stage. Additionally, high temperatures and 
humidity favor fungal growth, so carelessness of storage conditions favors a large amount of AFB1 
contamination occurring during storage [18]. 
The lack of regulations and the prevailing illegal production, storage and consumption of 
cannabis have meant a general unavailability of controls on its safety, including the absence of 
methods to monitor contamination. In this work, a rapid and sensitive enzyme immunoassay for 
measuring AFB1, primarily developed to monitor the presence of the toxin in eggs [19], was adapted 
for detecting AFB1 in cannabis products. Although several accurate and sensitive immunoenzymatic 
kits for AFB1 detection are available on the market, the indiscriminate use of immunoassay kits 
originally developed and validated for application in specific matrices to monitor AFB1 in very 
different materials should be carefully evaluated. Therefore, samples of cannabis derivatives 
(inflorescence and leaves) legally sold under the requirement of THC content lower than 0.2% were 
collected in small retail outlets in Torino (Italy). The enzyme immunoassay was modified in order to 
comply with the effect of the herbaceous matrix and the modified assay was in-house validated. A 
chromatographic-tandem mass spectrometry method was also developed to confirm accuracy of the 
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enzyme immunoassay. Finally, the sensitive enzyme immunoassay was used to measure AFB1 
contamination in 14 samples of cannabis products. 
2. Results 
2.1. Enzyme Immunoassay Adaptation to AFB1 Detection in Cannabis Products 
Extraction of the aflatoxin B1 from cannabis leaves and seeds was carried out by partitioning in 
80% methanol, as previously reported for AFB1 extraction from several kinds of medical plants 
[20,21]. 
The enzyme immunoassay used in this work was initially developed for measuring aflatoxins 
in eggs [19] and consisted of a direct competitive immunoassay, in which a polyclonal antibody raised 
against aflatoxin M1 linked to bovine serum albumin (BSA) (antiM1-pAb) was adsorbed onto the 
polystyrene of microplate wells. The target compound (AFB1) and the enzyme probe (AFB1 linked 
to horse radish peroxidase, AFB1-HRP) competed for binding to the anchored antibody. After 
removing unbound fractions by washing the plate, the signal generated by the enzyme was 
developed and measured. The time required to complete the analysis was 30 min. In previous work, 
we also produced a second polyclonal antibody using AFB1 linked to BSA as the immunogen (antiB1-
pAb). The antiB1-pAb showed higher selectivity towards AFB1 compared to the antiM1-pAb and 
was used in this work. Therefore, optimal AFB1-HRP and antiB1-pAb concentrations were defined 
ex-novo through the checkerboard titration approach. Other assay parameters were also re-
evaluated. In particular, AFB1-HRP and antiB1-pAb concentrations and time of reactions were 
decided upon providing a signal of the blank of approximately 1.5 UA and an IC50 of the calibration 
curve below 1 ng mL-1. Other parameters were defined based on minimizing matrix effect. Hence, 
extracts were fortified with known concentrations of AFB1 and the relative matrix effect (ME%) was 
calculated as follows: 
ME% = (AFB1 measured in the fortified extract − AFB1 measured in the non-fortified extract) / 
AFB1 added × 100 [22]. 
As the scope of the re-optimization of the enzyme immunoassay was intended for coping with 
new interference in AFB1 quantification due to the specific composition of the cannabis matrix, 
recovery was measured by fortifying the extract, which included potential interfering substances 
deriving from the sample. 
A modification of the pristine protocol was considered for statistically significant improvement 
of the obtained ME% rate. 
Two samples (representative of leaves and inflorescence) collected in a small local retail outlets 
were extracted and, using the methanolic extracts fortified with AFB1, the following parameters were 
studied: (1) dilution of the methanolic extract with water; (2) volume of the diluted extract to be added 
to the reaction well; (3) time for the immuno- and enzymatic reactions; (4) nature of the buffer for 
AFB1-HRP dilution; and (5) composition of the washing solution. 
In particular, we observed that a precipitate formed when the methanolic extracts were diluted 
with water; however, filtration and centrifugation to remove the particulate matter caused a dramatic 
loss of the toxin, measured by recovery values below 50%. Then, the raw suspension was diluted 1 + 
1 and added directly to the wells. Higher dilution rate (1 + 3) decreased the sensitivity of the assay 
(because of sample dilution) without increasing recovery rates, while using the undiluted extract 
produced a strong matrix effect evidenced by a large overestimation of the AFB1. For avoiding 
excessive matrix interference, the sample volume was reduced to one half (further reducing sample 
volume was ineffective for increasing recovery and halved the sensitivity). The pH of the buffer used 
for the immunoreaction and of the washing solutions was also modified in order to obtain satisfying 
recovery rates. Specifically, lowering the pH of both solutions to 5.0 allowed us to suppress most of 
the matrix interference. On the contrary, modification of composition (salts and additives) of buffers 
did not allow us to significantly improve recovery rates (Figure S1). Finally, the time of reactions was 
defined to limit the overall time required for completing the analysis while providing a signal of the 
blank that was measured with acceptable precision (>1 UA). The total time for the analysis was 40 
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min, which is quite low for microplate-based immunoassays and acceptable for the intended use as 
a first-level screening analysis. The experimental conditions considered in the study and the protocol 
optimized for AFB1 detection in cannabis are shown in Table 1. Several parameters of the pristine 
protocol needed to be modified to achieve acceptable recovery rates in the detection of AFB1 in 
cannabis products instead of in egg yolk. This finding pointed out that the use of commercial kits 
originally intended for specific applications to different commodities without modifications can lead 
to inaccuracy and should be discouraged. 
Table 1. Protocol for the detection of aflatoxin B1 (AFB1) in cannabis leaves and flowers. 
Variable Pristine Protocol 
Deduced from [19] 
Conditions Considered in This Work 1 
volume of 
standard/sample 100 µL 25, 50, 100 µL 
Dilution factor of 
methanol extract  
1+1 1+0, 1+1, 1+3 
Buffer for diluting AFB1-
HRP  PBST pH 7.4 
PBS/T pH 5.0, 6.0, 7.4 
MES/T pH 6.0 
phosphate/citrate/T pH 6.0 
Tris/T pH 7.4, 8.5 
Washing solution 
composition  
0.3 M NaCl + Tween 20 0.05% Tween 20, 0.3 M NaCl/T, PBS/T pH 
7.4, PBS/T pH 5.0  
Time of reaction 15′ + 15′ 15′ + 15′, 25′ + 15′, 15′ + 25′ 
1 The conditions selected for the enzyme immunoassay are highlighted in bold. 
A typical calibration curve for measuring AFB1 obtained in the optimized conditions is shown 
in Figure 1. 
 
Figure 1. The mean calibration curve obtained by averaging results from 6 individual curves carried 
out on six days. The limit of detection and the quantification interval calculated according to different 
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methods are shown by grey areas: (a) signal-to-noise method [22,23], (b) IC10/20-80 method [24–27], (c) 
error profile method [28], and (d) back calculation method [29]. 
2.2. Analytical Figures of Merits of the Enzyme Immunoassay 
Using 6 calibration curves, generated on different days and by using 6 calibrators measured in 
duplicate on each day, we studied the reproducibility of the calibration (Table 2) and calculated the 
limit of detection (LOD) and the range of quantification (ROQ) of the assay (Table 3 and Figure 1). 
Signals recorded on each day were normalized by the signal of the calibrator containing no AFB1 (B0). 
The LOQ and ROQ were estimated according to four methods, variously applied to competitive 
immunoassays: the signal-to-noise method [22,23], the IC10/20–80 method [24–27], the error profile 
method [28], and the back-calculation method [29]. 
Table 2. Parameters of the calibration curve fitting. Mean ± SD of the parameter were calculated from 
6 curves obtained on different days. The fit was obtained from 6 calibrators, including the blank. Each 
calibrator was measured in duplicate on each day. The 4-parameter logistic model was used for curve 
fitting. 
Parameter Mean ± SD 
Bmax (UA) 1.7 ± 0.2 
Bmin (UA) 0.08 ± 0.01 
IC50 (ng mL−1) 0,8 ± 0.1 
Slope −1.26 ± 0.05 
Table 3. Analytical figures of merits of the enzyme immunoassay for measuring AFB1 estimated 
according to different definitions of limit of detection (LOD) and range of quantification (ROQ) 
reported in the literature [22–28]. 











B0–3sd0 0.2 linearity (y vs log 
x) 
0.2–2.5 [22,23] 
Bmax inhibition IC10 0.12 IC20–IC80 0.15–4 [24–27] 
Error profile RSD% = 50% 0.2 RSD% = 50% 0.2–14 [28] 
Back-calculation Inaccuracy = 25% 0.35 Inaccuracy = 20% 0.4–2 [29] 
The calibration parameters were acceptably repeatable within different analytical sessions and 
days. The limit of detection varied depending on the method used for its estimation between 0.12 ng 
mL−1 (Bmax inhibition) and 0.35 ng mL−1 (back-calculation method). The quantification range also 
varied depending upon the method used to calculate it. Especially, the back-calculation method gave 
the narrower interval (0.4–2 ng mL−1) while according to the error profile method, the quantification 
range spanned from 0.2 to 14 ng mL−1 (Figure 1). The LOD varied among methods by a factor of 3 
and the ROQ approximately by one order of magnitude. Whatever the method, the enzyme 
immunoassay showed high sensitivity. 
Selectivity towards other mycotoxins was measured by calculating the cross-reactivity (CR), 
defined as follows: CR% = IC50 AFB1 / IC50 mycotoxin × 100 (Table S1). The selectivity trend was 
similar to the one observed previously for the same antibody [16]. In details, other compounds in the 
class of aflatoxins showed a certain degree of cross-reactivity, which ranged from 2.0% (AFM1) to 
25.3% (AFG1). Other mycotoxins with unrelated structures (i.e., ochratoxin A, zearalenone and 
fumonisins) did not interfere at all. 
2.3. Measuring AFB1 in Cannabis Products by the Enzyme Immunoassay 
The trueness of the assay was studied by recovery experiments. Two cannabis samples (#JA, 
made of leaves, and #DI comprising inflorescence) were analyzed directly and after fortification of 
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the raw sample (10 and 20 ng/g of AFB1). Apparently, sample #DI contained AFB1 (9.6 ng g−1), while 
sample #JA showed an apparent AFB1 content of 2.8 ng g−1 (corresponding to 0.28 ng mL−1 in the 
extract). This value was below the LOD estimated by the back-calculation method, while exceeding 
those calculated by the other methods. Sample #JA was then diluted 1 + 1, 1 + 3, and 1 + 7 with the 
extraction solvent and analyzed again. We expected that sample dilution would produce a 
proportional signal increase. On the contrary, signals were randomly scattered. We conclude that 
AFB1 content of sample #JA was below the detection limit of the assay; therefore, we assumed the 
LOD calculated by the back-calculation method as the most reliable for determining AFB1 in cannabis 
samples. According to the assignment of sample #JA as containing undetectable amounts of AFB1, 
satisfactory recovery rates (83–113 %, Table S2) were obtained for both samples. 
The reproducibility of the enzyme assay was evaluated by measuring one sample in six 
replicates within the same day (intra-assay repeatability) and five samples in duplicates on two 
different days (inter-assay variability). The intra- assay relative standard deviation (RSD %) and the 
mean of inter-assay RSD% were 11.8% and 13.8%, respectively. 
2.4. Liquid Chromatography Tandem Mass Spectrometry Determination of AFB1 in Cannabis Products 
To validate the enzyme immunoassay, a HPLC-MS/MS method for measuring AFB1 in cannabis 
products was developed in-house by adapting the method of Zheng et al., previously reported for 
the detection of major aflatoxins in medicinal herbs [30]. The method of Zheng et al. involved the 
analysis of the crude herbal extract without purification or pre-concentration and allowed the 
differentiation of various aflatoxins. The separation was obtained by a gradient elution in reverse 
phase liquid chromatography and the detection was in the single reaction monitoring (SRM) mode. 
To comply with matrix interference, AFM1 was used as the internal standard, provided that AFM1 
forms from the animal metabolism and then its presence in herbal extract could be excluded. The 
linearity of the calibration was confirmed between 5–40 ng mL−1 (y=0.56x – 0.67, r2=0.992, Figure S2) 
and the LOD and LOQ were calculated as 1.8 and 5.8 ng mL−1 (corresponding to 18 and 58 ng g−1 in 
the sample), respectively. The limit of detection of the HPLC-MS/MS method was five to ten times 
higher than the one calculated for the enzyme immunoassay (depending on the method used to 
calculate this last). The poor sensitivity compared to chromatography coupled to mass spectrometry 
[31] was due to the fact that we analyzed the crude extracts without applying any clean-up or pre-
concentration and that we did not optimize the method. To evaluate matrix interference four samples 
were analyzed by the HPLC-MS/MS method. All samples contained AFB1 below the limit of 
detection of the method. The extracts from four samples (two extracts for each sample,) were then 
fortified with 10 ng mL−1 of AFB1. Relative matrix effect values for fortified samples ranged from 81 
to 123% with a certain variability also among duplicate samples (Table 4). 
Table 4. AFB1 content in cannabis products from small local retails as measured by the enzyme 
immunoassay and by the HPLC-MS/MS and matrix effect for sample extracts fortified with 10 ng mL−1 
of AFB1. 
Sample id # 
Enzyme Immunoassay HPLC-MS/MS 
AFB1 ± SD (ng g-1)  ME a (%) AFB1 ± SD (ng g−1) ME a (%) 
NH-1 12.1 ± 0.9 86 <LOD c 74 
NH-2 14.8 ± 2.6 111  <LOD c 91 
GA-1 <LOD b 118 <LOD c 81 
GA-2 8.7 ± 0.1 117 <LOD c 96 
WA-1 <LOD b 104 <LOD c 103 
WA-2 <LOD b 116 <LOD c 123 
EJ-1 <LOD b 102 <LOD c 123 
EJ-2 <LOD b 103 <LOD c 118 
VW 13.8 ± 0.2 118 <LOD c 99 
AF <LOD 78 <LOD c 119 
GS <LOD 136 <LOD c 91 
Toxins 2020, 12, 265 7 of 13 
 
DP 13.4 ± 1.8 86 <LOD c 92 
BE 11.5 ± 1.1 126 <LOD c 83 
LE <LOD 98 <LOD c 85 
AH <LOD 116 <LOD c 100 
JA 17.7 ± 0.2 - d - d - d 
DI 9.7 ± 0.9 - d - d - d 
SO 8.6 ± 0.4 - d - d - d 
a ME value was calculated as (AFB1 measured in the fortified sample—AFB1 measured in the raw 
sample)/ AFB1 added*100. For the enzyme immunoassay, fortified extracts were diluted 1:10 before 
analysis. b The value obtained from the back calculation method (3.5 ng g−1) was considered. c LOD 
for the HPLC-MS/MS method was 18 ng g−1. d Not determined. 
2.5. Method Comparison: Enzyme Immunoassay and HPLC-MS/MS 
To further confirm that the enzyme immunoassay was not affected by the interference of the 
matrix and by its intrinsic variability (leaf, flowers, seeds and other parts of the cannabis plant were 
occasionally present in the samples collected in small retail outlets), four samples were divided into 
sub-samples (two sub-samples were generated for each sample) and extracted and analyzed on 
different days. As observed for the HPLC-MS/MS validation, again certain variability between sub-
samples was observed (Table 4). 
In parallel, a further total of 10 samples was extracted and analyzed directly after fortifying the 
extracts with 10 ng mL−1 of AFB1 by the in-house-developed HPLC-MS/MS method and by the 
enzyme immunoassay (fortified extracts were analyzed by the enzyme immunoassay after a 1:10 
dilution in the extraction solvent to comply with the ROQ). All samples resulted containing AFB1 
below the limit of detection of the HPLC-MS/MS method, while according to the enzyme 
immunoassay 50% of samples were contaminated above the LOD. The mean AFB1 content was 
measured to be 12.3 ng g−1 and the contamination level varied between 8.6 and 17.7 ng g−1 (Table 4). 
The mean ME% calculated for fortified extracts were 108% (78–136%) and 99% (74–123%) for the 
enzyme immunoassay and the HPLC-MS/MS method, respectively. Results which agreed were 
obtained in the two analytical methods, although the enzyme immunoassay showed a tendency to 
overestimate AFB1 contamination in comparison to the HPLC-MS/MS method. (Figure 2 and Table 
4). 
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Figure 2. Bland-Altman plot for comparing the enzyme immunoassay and HPLC-MS/MS methods to 
measure AFB1 in cannabis products. Data are randomly scattered, with a positive bias of +16, 
representing the tendency of the enzyme immunoassay to overestimate AFB1 compared to the HPLC-
MS/MS method. 
3. Discussion 
A rapid, accurate and sensitive enzyme immunoassay was established for the measurements of 
AFB1 in cannabis products, based on previously developed bio reagents. The re-evaluation of assay 
parameters and particularly of the pH of the buffers and the washing solution allowed us to adapt 
the assay to the novel matrix and to mitigate the influence of the large variability in the composition 
of extracts from different part of the cannabis plant. To comply with possible variability of the matrix, 
a prudential limit of detection was decided, which was calculated from the inaccuracy of repeated 
calibration curves [29] and validated by dilution and recovery experiments on two cannabis samples. 
Actually, the limit of detection (LOD) and the range of quantification (ROQ) are variously defined 
for immunological-based assays, in particular for competitive immunoassays, where the signal is 
inversely (and not linearly) correlated to the concentration of the target. Sometimes, the signal-to-
noise ratio method [22,23] is used to calculate the LOD, which is then assumed as the concentration 
of the analyte that corresponds to the signal of the standard 0 (B0) minus two or three standard 
deviation of the standard 0. However, this method has some limitations when applied to non-linear 
curve fitting. As an alternative, especially suitable for competitive immunoassays in which data are 
fitted by the four parameter logistic model (4-PL), a certain level of inhibition of the maximum 
binding (Bmax) is considered to estimate the LOD and ROQ [24–27,32,33]. The inhibition levels most 
frequently considered for the purpose are 90% for estimating the LOD, and 85%–15% [32,33] or 80–
20% [24–27] for the ROQ, respectively. The rationale beyond this approach is represented by the fact 
that the typical standard curve of competitive immunoassays has a sigmoidal shape and the upper 
and lower parts of the curve are strongly imprecise. However, the inhibition levels are, in some way, 
arbitrarily defined. A more robust identification of significant inhibition levels is based on the use of 
the error profile curve (also called precision profile). In this method, the relative standard deviation 
(RSD %) of repeated experiments is calculated for various concentrations of the analyte (typically for 
calibrators) and plotted towards the calibrators’ concentrations. The ROQ and LOD are defined as 
the interval of concentrations that can be measured with a certain precision [28,34]. However, the 
level of acceptable imprecision is debated. Some authors have 30% and 10% for estimating the LOD 
and ROQ, respectively [30], while others considered 50% as the maximum acceptable imprecision 
[32]. In addition, modelling precision profile is complicated and discourages the application of this 
criterion. A concept similar to using the precision profile is the back-calculation method, in which the 
concentration of the calibrators is estimated by the fit of the curve and the interval of quantification 
is defined as the concentrations estimated with an acceptable accuracy (±20%) [29,34]. The limit of 
detection is calculated as the lower concentration that provides inaccuracy below 25% [29]. 
In this work, we used repeated calibration curves to estimate LOD and ROQ according to the 
four approaches described above. The values obtained for the LOD varied approximately by a factor 
of three depending on the approach applied; the IC10/20-80 method provided the lowest value (0.12 ng 
mL−1) while the highest value (0.35 ng mL−1) was calculated according to the back-calculation method. 
The quantification range varied also upon the method used to calculate it and to a larger extent than 
the LOD. The back-calculation method provided the narrower interval (0.4–2 ng mL−1) and the error 
profile method the largest interval (0.2 to 14 ng mL−1). From a theoretical point of view, the error 
profile and the back-calculation approaches are the more robust; however, they require several 
experiments and complicated mathematical modeling. The signal-to-noise ratio allows the obtaining 
of a reasonable compromise, although it is based on the assumption of the linear dependency of the 
signal on the analyte concentration, which is not realistic for ligand-binding assays. The simplest 
method to calculate the LOD and ROQ is that based on defining levels of inhibition of Bmax. In this 
case, it is sufficient to fit the data and interpolate the values corresponding to IC10, IC20 and IC80. The 
simplicity of the calculation explains the success of the approach; however, the enzyme immunoassay 
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here reported produced a significantly lower LOD compared to other approaches. Moreover, the IC10 
limit was not robust when considering the capability of the assay for detecting AFB1 in real samples. 
The LOD calculated form other methods allowed us to reliably measure AFB1 in the extract from 
different cannabis products. The comparison suggests some precaution in comparing different 
competitive immunoassays where the analytical performance was calculated differently. 
The estimated LOD for measuring AFB1 in cannabis leaves and flowers (3,5 ng g−1) was higher 
than that recently reported by Narváez et al. [31]. However, the ultra-high sensitivity was reached by 
using ultra-high performance liquid chromatography coupled to high resolution tandem mass 
spectrometry and requested a preliminary clean-up of the extracts. The enzyme immunoassay was 
applied to extracts without additional treatment and required cost-efficient equipment and very 
limited training of personnel to be operated, thus allowing wide applications in low resource settings 
and for the affordable monitoring of the safety of the cannabis product, especially considering 
recreational use and employment as food supplement. The limited number of samples analyzed in 
this work does not permit us to draw conclusions about the risk of AFB1 contamination in cannabis 
products legally sold in Italy; however the 50% of samples we analyzed, showing AFB1 contents 
above the detectable level and above the maximum limit admitted for commodities intended for 
direct human consumption [35], shed light on the need for increasing controls and, more generally, 
investigating the level of contamination from mycotoxins of such products. These preliminary results 
also suggest implementing appropriate surveillance of aflatoxin contamination of cannabis products 
intended for medical uses. In addition, specific analytical methods to measure other toxic metabolites 
in cannabis products should be developed in order to effectively protect consumers’ health. 
4. Materials and Methods 
4.1. Reagents and Apparatus 
Bovine serum albumin (BSA), 3,3′5,5′-tetramethylbenzidine liquid substrate (TMB), and 
Aflatoxin B1, aflatoxin M1, aflatoxin B2, aflatoxin G1, aflatoxin G2, ochratoxin A (OTA), 
deoxynivalenol (DON), fumonisin B1 (FB1), and zearalenone (ZEA) standard solutions were 
purchased from Sigma Aldrich (Merck, Darmstadt, Germany). Methanol (HPLC grade), microplates 
and all other chemicals were obtained from VWR International (Milan, Italy). Rabbit polyclonal 
antibodies directed towards aflatoxin B1 (anti-AFB1) and aflatoxin B1 conjugated to horse radish 
peroxidase (AFB1-HRP) were prepared in the laboratory as described in [16]. Optical density at 450 
nm was measured by a Multiskan microplate reader (ThermoScientific, Waltham, MA, USA). Extract 
were centrifuged in a refrigerated centrifuge (BR, Juan, France). 
4.2. Competitive Direct ELISA 
The assay was carried out as described previously, with minor modifications to assure optimal 
detectability, as follows. 
The immunoreactive wells were prepared by adsorbing overnight anti-AFB1 antibodies diluted 
in carbonate/bicarbonate buffer (pH 9.6). After washing with 0.05% Tween 20, uncoated well surface 
was saturated with 0.5% BSA dissolved in phosphate buffer supplied with 0.15M NaCl and 0.05% 
Tween 20 (PBST_BSA) for 1 h at room temperature, followed by three washings with 0.05% Tween 
20. 
Calibration curves were generated by mixing 150 µL of AFB1-HRP (0.05 µg mL−1) in PBST_BSA 
and 50 µL of AFB1 standards diluted in aqueous methanol (40%) at concentrations ranging from 0 to 
10 ng mL−1. After 15 min incubation in immunoreactive wells, unbound reagents were removed by 
five washings with PBST. Color due to TMB oxidation was stopped after 25 min incubation by adding 
sulphuric acid (2M) and measured at 450 nm. For cannabis samples, extracts prepared as described 
below were directly added to wells instead of AFB1 standards. All standards were measured in 
duplicate. 
Unknown sample concentrations were determined by interpolation on the calibration curve, 
where the signal was plotted against the analyte concentration. For each experiment, a calibration 
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curve was determined by a nonlinear regression analysis of the data using the four-parameter logistic 
equation. 
Reproducibility of the calibration was evaluated by comparing curves obtained on six days. On 
each day, the normalized signal (S/S0, %) was calculated as the signal produced by each calibrator (S) 
divided by the signal of the standard 0 (S0). Inter-day reproducibility was calculated as the coefficient 
of variation of the mean of normalized signals for each AFB1 level. In addition, percentage error of 
concentration was defined by back-calculating concentrations at each AFB1 level on each day and 
then considering the coefficient of variation of back-calculated concentrations. 
The limit of detection and working interval of concentrations were estimated from the 
calibration curve obtained by averaging six individual curves according to different methods from 
the literature [22–29]. 
In particular, for the signal-to-noise method, the mean value and the standard deviation of the 
calibrator “0” (blank) were calculated from 12 replicates (6 days × 2 replicates on each day). The 
signal-to-noise ratio was set at 3 and the LOD was calculated as the concentration corresponding to 
the blank minus three standard deviation of the blank. The ROQ was estimated from the curve as the 
interval that can be considered as approximatively linear, even if a competitive dose-response curve 
is intrinsically non-linear. The IC10/20–80 method estimates the LOD as the 10% inhibition of the 
maximum binding (Bmax), while the ROQ is represented by values comprises between 20% and 80% 
of Bmax inhibition. In this case, Bmax is obtained from the 4-PL fit of data. 
The error profile and the back-calculation methods encompass the measuring of the coefficient 
of variation and the inaccuracy at different levels of the target and plotting them towards the levels. 
LOQ and ROQ are defined accordingly with acceptable imprecision and inaccuracy. The error profile 
curve and the inaccuracy curve were also generated from repeated measurements of the calibrators 
(n = 12). The error profile curve was obtained by plotting the RSD% of calibrators towards their 
concentration, while the inaccuracy was obtained from the back-calculation of calibrator 
concentrations obtained by the 4 PL-fit compared to the true value for each calibrator. 
4.3. Cross-Reactivity Study 
Calibration curves as described above were generated for other aflatoxins (AFG1, AFB2, AFG2, 
and AFM1) and unrelated mycotoxins (ochratoxin A, deoxynivalenol, fumonisins B1, and 
zearalenone). The same protocol was applied; however, a larger concentration range was investigated 
for unrelated mycotoxins (0–100 ng mL−1). 
Relative cross-reactivity was calculated as follows: 
CR% = (IC50 AFB1 / IC50 mycotoxin) × 100  
where IC50 is the mycotoxin concentration which causes 50% inhibition of the maximum observed 
signal. 
4.4. Samples and Sample Preparation 
Fourteen samples of legal cannabis were purchased in small retail outlets in Torino (Italy) during 
the period January-March 2019. Samples were roughly minced, accurately weighted (0.2 g) and 
extracted with 2 mL of aqueous methanol (80%) by vortex mixing for 2 min and centrifuging at 5000× 
g for 15 min (4 °C). Supernatants were diluted 1 + 1 with water and analyzed by the direct competitive 
ELISA. Depending on sample availability, 1-3 sub-samples were separately weighted and extracted. 
Extracts were analyzed in quadruplicate. 
Two samples that did not show any detectable residues of aflatoxins were taken as the blank for 
recovery experiments. Fortified samples were prepared by adding 10, and 20 ng g−1 of AFB1, to the 
minced samples, leaving overnight under a hood for drying the solvent and homogenizing. 
4.5. Liquid Chromatography Coupled to Tandem Mass Spectrometry Detection of AFB1 
The chromatographic separation was achieved by an Accela System (ThermoScientific, 
Waltham, MA, USA) and using a kinetic XB-C18 column (150 mm × 4,6 mm; 5 µm form Phenomenex, 
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Torrance, CA, USA). Ammonium acetate (4 mmol L−1) and 0.1% formic acid (A) and methanol (B) 
were used as the mobile phase. Gradient elution was programmed as follows: 5 min isocratic elution 
at 40% B, linear increase up to 80% in 15 min, then up to 100% in further 5 min and finally, isocratic 
elution at 100% for further 5 min. The total run time including re-conditioning was 30 min. Detection 
was obtained by the SRM method on a LCQ Fleet (ThermoScientific, Waltham, MA, USA), equipped 
with the electrospray source operating in positive mode. Transitions followed for AFB1 and AFM1 
are detailed in Table S3. For quantification, the calibration curve was built by plotting thee area of 
AFB1 peak divided by the area of AFM1 peak towards AFB1 concentrations (Figure S1). The LOD 
and LOQ were calculated from equations:  
LOD = (3 × SD)/m  
LOQ = (10 × SD)/m  
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/4/265/s1: Figure 
S1: Optimization of the composition of AFB1-HRP diluent and of the washing solution, Figure S2: Calibration 
curve for the HPLC-MS/MS method to measure AFB1 in cannabis products, Table S1: Cross-reactivity of the 
enzyme immunoassay towards mycotoxins, Table S2: Recovery rates for two cannabis samples fortified with 
AFB1 and analyzed by the enzyme immunoassay, Table S3: SMR transitions for AFB1 quantification in cannabis 
products. 
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